Patent US4157520A successfully refreshed from Google Patents.
Patent US3296451A successfully refreshed from Google Patents.
Patent US2275853A successfully refreshed from Google Patents.
Patent US5571784A successfully refreshed from Google Patents.
US5571784A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of VWF-containing concentrates as a therapy which is employed in combination with antithrombotic and fibrinolytic therapy
Assignee: Siemens Healthcare Diagnostics GmbH Germany
•
Filing: 1995-10-18
•
Granted: 1996-11-05
•
Expires: 2015-10-18
Abstract
Abstract The invention relates to the administration of von Willebrand factor (vWF)-containing drugs in association with the therapeutic use of blood anticoagulants, either on their own or together with fibrinolytics. The administration, which is for the purpose of reducing the risk of hemorrhages in patients, can take place either at the same time or following the anticoagulant and lytic treatment. A therapy principle is described which separates, during therapy, the desirable effect of anticoagulation and/or fibrinolysis from the undesirable side effect of hemorrhagic tendency.
Inventors
- 👤 Martin Reers
- 👤 Gerhard Dickneite
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 23:25
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/36; A61K38/37; A61P; A61P7/00; A61P7/02; A61P7/04
Claims Analysis
Total Claims: 3
Claim 1
Independent Claim
39 words
A method for decreasing the bleeding side effect in a patient caused by administering anticoagulant and/or fibrinolytic agents comprising administering to said patient a therapeutically active amount of von Willibrand Factor, or a fragment having von Willibrand Factor activity.
Claim 2
Independent Claim
39 words
A method for decreasing the bleeding side effect in a patient caused by administering anticoagulant and/or fibrinolytic agents comprising administering to said patient a therapeutically active amount of von Willibrand Factor, or a fragment having von Willibrand Factor activity.
Claim 3
Dependent Claim
30 words
The method according to claim 1, wherein in addition to said von Willibrand Factor, or a fragment having von Willibrand Factor activity, an antithrombotic agent and/or fibrinolytic agent is administered.
References Cited (Backward Citations)
US5198349A
Cited
US5200510A
Cited
US4774323A
Cited
US5112950A
Cited
EP0367713B1
Cited
US5204323A
Cited
US5204323B1
Cited
US5408039A
Cited
WO1992020361A1
Cited
US5366869A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-11-05 | 2000-05-06 | 2000-11-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-11-05 | 2004-05-06 | 2004-11-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-11-05 | 2008-05-06 | 2008-11-05 | $7700.00 | Window Closed / Lapsed |